These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25950595)

  • 1. Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.
    Mitchell SG; Gryczynski J; Schwartz RP; Myers CP; O'Grady KE; Olsen YK; Jaffe JH
    J Psychoactive Drugs; 2015; 47(2):149-57. PubMed ID: 25950595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and quality of life of opioid-dependent pregnant women in Austria.
    Metz VE; Comer SD; Wuerzl J; Pribasnig A; Fischer G
    Arch Womens Ment Health; 2014 Dec; 17(6):529-39. PubMed ID: 25023716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.
    Mitchell SG; Gryczynski J; Schwartz RP; O'Grady KE; Olsen YK; Jaffe JH
    Drug Alcohol Depend; 2013 Mar; 128(3):222-9. PubMed ID: 22999817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.
    Cushman PA; Liebschutz JM; Anderson BJ; Moreau MR; Stein MD
    J Subst Abuse Treat; 2016 Sep; 68():68-73. PubMed ID: 27431049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
    Holland R; Maskrey V; Swift L; Notley C; Robinson A; Nagar J; Gale T; Kouimtsidis C
    Addiction; 2014 Apr; 109(4):596-607. PubMed ID: 24304349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment.
    Giacomuzzi SM; Ertl M; Kemmler G; Riemer Y; Vigl A
    ScientificWorldJournal; 2005 May; 5():452-68. PubMed ID: 15925962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
    Strain EC; Stitzer ML; Liebson IA; Bigelow GE
    J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.
    Streck JM; Ochalek TA; Badger GJ; Sigmon SC
    Exp Clin Psychopharmacol; 2018 Aug; 26(4):403-409. PubMed ID: 29939049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine Treatment for Opioid Use Disorder in Community-Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results.
    Galanter M; Femino J; Hunter B; Hauser M
    Am J Addict; 2020 Jul; 29(4):271-278. PubMed ID: 32162434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
    D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
    J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.
    Kowalczyk WJ; Moran LM; Bertz JW; Phillips KA; Ghitza UE; Vahabzadeh M; Lin JL; Epstein DH; Preston KL
    Am J Drug Alcohol Abuse; 2018; 44(5):502-511. PubMed ID: 29634425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.